Thyroid hormone is highly permissive in angioproliferative pulmonary hypertension in rats

European Respiratory Journal

Volumn 41, Issue 1, 2013, Pages 104-114

  Al Husseini, Aysar ^a   Bagnato, Gianluca ^a   Farkas, Laszlo ^a   Gomez Arroyo, Jose ^a   Farkas, Daniela ^a   Mizuno, Shiro ^a,b   Kraskauskas, Donatas ^a   Abbate, Antonio ^a   Van Tassel, Benjamin ^a   Voelkel, Norbert F ^a   Bogaard, Harm Jan ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Integrins; Pulmonary circulation; Thyroid hormone

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROPYLTHIOURACIL; THYROID HORMONE; THYROXINE; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HORMONAL REGULATION; HORMONE DETERMINATION; HYPOXIA; LUNG VASCULAR RESISTANCE; MALE; MOLECULAR DYNAMICS; NONHUMAN; PHENOTYPE; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; THYROIDECTOMY;

ANIMALS; HYPERTENSION, PULMONARY; MALE; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; THYROID HORMONES;

EID: 84872198058     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00196511     Document Type: Article

References (34)

1. Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-285.
2. Xu W, Koeck T, Lara AR, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA 2007; 104: 1342-1347.
3. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007; 153: 1037-1047.
4. Rai PR, Cool CD, King JA, et al. The cancer paradigm of severe angioproliferative pulmonary hypertension. Am J Respir Crit Care Med 2008; 178: 558-564.
5. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
6. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009; 34: 1219-1263.
7. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-1815.
8. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350: 886-895.
9. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
10. Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol 2010; 6: 431-443.
11. Davis FB, Mousa SA, O'Connor L, et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 2004; 94: 1500-1506.
12. Bergh JJ, Lin HY, Lansing L, et al. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005; 146: 2864-2871.
13. Davis PJ, Davis FB, Mousa SA. Thyroid hormone-induced angiogenesis. Curr Cardiol Rev 2009; 5: 12-16.
14. Herget J, Frydrychova M, Kawikova I, et al. Thyroxine treatment increases the hypoxic pulmonary vasoconstriction in isolated lungs from thyroidectomized rats. Bull Eur Physiopathol Respir 1987; 23: 217-221.
15. Oka M, Homma N, Taraseviciene-Stewart L, et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007; 100: 923-929.
16. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15: 427-438.
17. Bogaard HJ, Natarajan R, Henderson SC, et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009; 120: 1951-1960.
18. Pass D, Freeth G. The rat. ANZCCART News 1993; 6: 1-4.
19. Chemla D, Castelain V, Humbert M, et al. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest 2004; 126: 1313-1317.
20. Richalet JP, Letournel M, Souberbielle JC. Effects of high-altitude hypoxia on the hormonal response to hypothalamic factors. Am J Physiol Regul Integr Comp Physiol 2010; 299: R1685-R1692.
21. Moncloa F, Guerra-Garcia R, Subauste C, et al. Endocrine studies at high altitude. I. Thyroid function in sea level natives exposed for two weeks to an altitude of 4300 meters. J Clin Endocrinol Metab 1966; 26: 1237-1239.
22. Zayour D, Azar ST, Azar N, et al. Endocrine changes in a rat model of chronic hypoxia mimicking cyanotic heart disease. Endocr Res 2003; 29: 191-200.
23. Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 2006; 6: 407-428.
24. Tanghetti E, Ria R, Dell'Era P, et al. Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. Oncogene 2002; 21: 3889-3897.
25. Benisty JI, McLaughlin VV, Landzberg MJ, et al. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest 2004; 126: 1255-1261.
26. Izikki M, Guignabert C, Fadel E, et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 2009; 119: 512-523.
27. Tu L, Dewachter L, Gore B, et al. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol 2011; 45: 311-322.
28. Badesch DB, Wynne KM, Bonvallet S, et al. Hypothyroidism and primary pulmonary hypertension: an autoimmune pathogenetic link? Ann Intern Med 1993; 119: 44-46.
29. Curnock AL, Dweik RA, Higgins BH, et al. High prevalence of hypothyroidism in patients with primary pulmonary hypertension. Am J Med Sci 1999; 318: 289-292.
30. Chu JW, Kao PN, Faul JL, et al. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002; 122: 1668-1673.
31. Nicolls MR, Taraseviciene-Stewart L, Rai PR, et al. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005; 26: 1110-1118.
32. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev 2010; 31: 139-170.
33. Rusnati M, Tanghetti E, Dell'Era P, et al. alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. Mol Biol Cell 1997; 8: 2449-2461.
34. Gomez-Arroyo JG, Saleem SJ, Mizuno S, et al. A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol 2012; 302: L977-L991.